Search Within

Ariela Noy

Formats
  1. Meeting Abstract (204)
  2. Journal Article (143)
  3. Research Letter (10)
  4. Book Section (6)
  5. Review (6)
  6. Editorial (2)
  7. Correspondence (1)
  8. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (373)
  2. Department of Medicine (373)
  3. Hematologic Malignancies, Division of (373)
  4. Lymphoma (373)
  5. Survivorship Research (163)
  6. Population Sciences Research Program (150)

More Groups

People
  1. Andrew Zelenetz (187)
  2. Paul Hamlin (144)
  3. David Straus (139)
  4. Steven Horwitz (138)
  5. Maria Palomba (131)
  6. Alison Moskowitz (118)

More People

Years
  1. 2025 (9)
  2. 2024 (27)
  3. 2023 (24)
  4. 2022 (15)
  5. 2021 (30)
  6. 2020 (26)

More Years

Publications
  1. Blood (166)
  2. Journal of Clinical Oncology (42)
  3. Hematological Oncology (19)
  4. Leukemia and Lymphoma (15)
  5. Blood Advances (13)
  6. Annals of Oncology (12)

More Publications

Publishers
  1. American Society of Hematology (179)
  2. American Society of Clinical Oncology (43)
  3. Wiley Blackwell (23)
  4. Elsevier Inc. (21)
  5. Taylor & Francis Group (15)
  6. Ferrata Storti Foundation (12)

More Publishers

Results (373)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Majority of transformed lymphomas have high SUVs on PET scanning similar to diffuse large B cell lymphoma (DLBCL)
    Meeting Abstract

    Weissler, M.; Noy, A.; Schoder, H.; Gonen, M.; Yeung, H.
    Blood (2006)

    Fulltext@MSK | Save
  • Infectious disease associations in advanced stage, indolent lymphoma (Follicular, FL and non-follicular, nFL): Developing a lymphoma prevention strategy
    Meeting Abstract

    Portlock, C. S.; Hamlin, P. A.; Noy, A.; Palomba, M. L.; Rosenzweig, L.; Walker, D.; Corcoran, S.; Chey, W. D.; Gaydos, C. A.; Schwartz, I.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-Cell lymphomas: Results of the MSKCC phase I/II experience
    Meeting Abstract

    O'Connor, O. A.; Hamlin, P. A.; Gerecitano, J.; Portlock, C. S.; Noy, A.; Moskowitz, C.; Straus, D. J.; Sarasohn, D.; Dumitrescu, O.; Pappanicholaou, J.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Early phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies
    Meeting Abstract

    O'connor, O.; Hamlin, P.; Neylon, E.; Moskowitz, C.; Portlock, C.; Noy, A.; Sirotnak, F.; Zelenetz, A.; Mould, D.; Horwitz, S.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL
    Meeting Abstract

    Moskowitz, C.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; O'Connor, O. A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Lessac-Chenen, S.; Weaver, A.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders
    Meeting Abstract

    Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Update in HIV lymphoma
    Journal Article

    Noy, A.
    Current Opinion in Oncology (2006)

    Fulltext@MSK | Save
  • Pralatrexate (10-propargyl-10-deazaaminopterin (PRX)), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity
    Meeting Abstract

    O'connor, O.; Hamlin, P. A.; Neylon, E.; Moskowitz, C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Cortelli, B.; Zelenetz, A. D.; Fleisher, M.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-Cell lymphomas: Minimal benefit when analyzed by intent to treat
    Meeting Abstract

    Horwitz, S.; Moskowitz, C.; Kewalramani, T.; Hamlin, P.; Straus, D.; O'connor, O.; Noy, A.; Portlock, C.; Nimer, S.; Palomba, M. L.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Early safety and efficacy analysis of a phase II study of sequential R-CHOP and Yttrium-90 ibritumomab tiuxetan (Zevalin((R))) for elderly high risk patients with untreated DLBCL
    Meeting Abstract

    Hamlin, P. A.; Moskowitz, C. H.; Wegner, B. C.; Portlock, C. S.; Straus, D. J.; Noy, A.; Dumitrescu, O.; Palomba, M. L.; Horwitz, S. M.; O'Connor, O. A.; more...
    Blood (2005)

    Fulltext@MSK | Save